PUBLISHER: DelveInsight | PRODUCT CODE: 2096450
PUBLISHER: DelveInsight | PRODUCT CODE: 2096450
Aortic Aneurysm Stent Grafts Market Summary
An aortic aneurysm stent graft is a fabric-covered metal mesh implant delivered through a catheter-based, minimally invasive procedure to reinforce a weakened, ballooning section of the aorta and prevent life-threatening rupture. The device is deployed inside the diseased segment of the aorta, where it excludes the aneurysm sac from systemic blood pressure while providing a durable conduit for blood flow. Because open surgical repair carries substantially higher perioperative morbidity and mortality, hospitals and specialty cardiovascular centers increasingly favor endovascular approaches, driving sustained demand for stent graft systems. The market is organized by product type across abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA) stent grafts; by procedure type across Endovascular Aneurysm Repair (EVAR), Thoracic Endovascular Aneurysm Repair (TEVAR), Fenestrated Endovascular Aneurysm Repair (FEVAR), and Branched Endovascular Aneurysm Repair (BEVAR); by graft design across standard, fenestrated, and branched configurations; by material across polyester (Dacron)-based, expanded polytetrafluoroethylene (ePTFE)-based, and hybrid-material grafts; and by fixation type across infrarenal and suprarenal fixation. Driven by an aging global population, expanding aneurysm-screening programs, and continuous device innovation supporting increasingly complex aortic anatomies, aortic aneurysm stent grafts have become the standard of care across the majority of elective and emergent aneurysm repairs worldwide.
Aortic Aneurysm Stent Grafts Market Key Growth Drivers
Key Companies in Aortic Aneurysm Stent Grafts Market
The competitive landscape is led by the following active device manufacturers:
Factors Contributing to the Growth of the Aortic Aneurysm Stent Grafts Market
Market Drivers
Rising Global Prevalence of Aortic Aneurysms and an Aging Population
The most fundamental driver of the aortic aneurysm stent grafts market is the rising global prevalence of abdominal and thoracic aortic aneurysms, a disease strongly correlated with age. Aneurysm risk rises sharply after age 65, and the disease disproportionately affects men with a history of smoking, hypertension, and atherosclerosis. As life expectancy increases across developed and emerging economies alike, the pool of patients at risk of aneurysm formation and rupture continues to expand. Aortic aneurysms are frequently asymptomatic until rupture, which carries a mortality rate exceeding 80%, making timely detection and repair a clinical priority. This growing, aging, at-risk population directly enlarges the addressable base for elective and emergent stent graft procedures, anchoring durable market growth through 2034.
Accelerating Shift from Open Surgical Repair to Endovascular Procedures
A structural shift toward minimally invasive treatment is a central growth engine for the market. Endovascular aneurysm repair delivers a catheter-based stent graft through the femoral arteries under imaging guidance, avoiding the large abdominal or thoracic incisions required by open surgical repair. Clinical evidence consistently shows endovascular repair carries substantially lower perioperative mortality than open surgery, alongside shorter hospital stays and faster return to normal activity, particularly important for the elderly and high-risk patients who make up the majority of the aneurysm population. In the United States, the large majority of abdominal aortic aneurysm procedures are now performed endovascularly rather than through open surgery. As hospitals and specialty cardiovascular centers continue to expand hybrid operating room capacity and physician training, the endovascular share of aneurysm repair volume is expected to keep rising, directly enlarging stent graft demand across the forecast period.
Market Restraints
Despite strong momentum, the aortic aneurysm stent grafts market faces material constraints. The high cost of advanced stent graft systems and the associated endovascular procedure, including imaging infrastructure and hybrid operating rooms, limits adoption in cost-sensitive and lower-reimbursement healthcare systems. The risk of endoleaks, graft migration, and the need for lifelong surveillance imaging and potential reintervention raise long-term costs and create durability concerns relative to open surgical repair in younger, lower-risk patients. Complex aortic anatomies, including short or angulated necks, small or heavily calcified access vessels, and extensive visceral-branch involvement, continue to limit endovascular eligibility for a meaningful share of patients despite advances in fenestrated and branched technology. A shortage of vascular surgeons trained in complex endovascular techniques constrains procedure volume growth in several regions, while reimbursement for premium fenestrated, branched, and polymer-sealed devices remains uneven across geographies. Open surgical repair continues to be favored in select younger and low-surgical-risk patients due to superior long-term durability data, tempering endovascular penetration at the margin. Together, these cost, durability, anatomical, workforce, and reimbursement barriers moderate the pace of growth, even as the underlying drivers of an aging population, screening expansion, and technological innovation remain firmly intact.
Aortic Aneurysm Stent Grafts Market Segment Analysis
The Aortic Aneurysm Stent Grafts by Product Type (Abdominal Aortic Aneurysm (AAA) Stent Grafts, Thoracic Aortic Aneurysm (TAA) Stent Grafts), Procedure Type (Endovascular Aneurysm Repair (EVAR), Thoracic Endovascular Aneurysm Repair (TEVAR), Fenestrated Endovascular Aneurysm Repair (FEVAR), Branched Endovascular Aneurysm Repair (BEVAR)), Graft Design (Standard Stent Grafts, Fenestrated Stent Grafts, Branched Stent Grafts), Material (Polyester (Dacron)-Based Stent Grafts, Expanded Polytetrafluoroethylene (ePTFE)-Based Stent Grafts, Hybrid Materials), Fixation Type (Infrarenal Fixation, Suprarenal Fixation), End User (Hospitals, Specialty Cardiovascular Centers, Ambulatory Surgical Centers (ASCs)), and Geography (North America, Europe, Asia-Pacific, and Rest of World).
By Type
Dominant Subsegment: Abdominal Aortic Aneurysm (AAA) Stent Grafts. The Abdominal Aortic Aneurysm (AAA) Stent Grafts category is expected to dominate the market.
Dominant: Abdominal Aortic Aneurysm (AAA) Stent Grafts ~ 61%
The abdominal aortic aneurysm (AAA) stent grafts segment accounted for 61% of the Aortic Aneurysm Stent Grafts market in 2025. AAA stent grafts are the leading product type because abdominal aortic aneurysms are substantially more prevalent than thoracic aneurysms, particularly among the aging, hypertensive, and smoking-history populations most at risk, and because EVAR for infrarenal AAA is the most mature, widely practiced, and best-reimbursed endovascular aortic procedure. Landmark clinical trials have demonstrated durable reductions in aneurysm-related mortality with AAA endovascular repair, and decades of clinical experience, favorable reimbursement policies, and broad physician familiarity reinforce widespread adoption. Leading devices in this segment, including Medtronic's Endurant family and W. L. Gore's Excluder AAA Device Family, benefit from extensive long-term outcomes data. While thoracic aortic aneurysm stent grafts are growing faster, propelled by rising TEVAR adoption and expanding indications for aortic dissection and transection, the sheer prevalence and procedural maturity of AAA repair secure the segment's leadership across the forecast period.
By Procedure Type
Dominant Subsegment: Endovascular Aneurysm Repair (EVAR). The Endovascular Aneurysm Repair (EVAR) category is expected to dominate the market.
Dominant: Endovascular Aneurysm Repair (EVAR) ~ 58%
The Endovascular Aneurysm Repair (EVAR) segment accounted for 58% of the Aortic Aneurysm Stent Grafts market in 2025. EVAR is the leading procedure type because it is the standard first-line treatment for anatomically suitable infrarenal abdominal aortic aneurysms, offering markedly lower perioperative mortality than open surgical repair alongside shorter hospital stays and faster recovery. The high prevalence of AAA relative to other aortic pathologies, combined with decades of accumulated clinical evidence, established reimbursement pathways, and broad training among vascular and interventional specialists, sustains very high EVAR procedure volumes globally. TEVAR is expanding quickly as thoracic aneurysm diagnosis rises and devices such as Terumo's RELAY Pro and Medtronic's thoracic portfolio gain expanded dissection and transection indications, while FEVAR and BEVAR are the fastest-growing procedure types as physicians extend endovascular treatment to complex juxtarenal, pararenal, and thoracoabdominal anatomies. Nonetheless, the scale and procedural maturity of standard infrarenal EVAR secure its leadership across the forecast period.
Aortic Aneurysm Stent Grafts Market Region Analysis
Dominant Region: North America
Dominant: North America ~ 44% (Largest)
North America accounted for 44% of the global Aortic Aneurysm Stent Grafts market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high and growing prevalence of aortic aneurysms among an aging population, an established Medicare-covered ultrasound screening pathway, broad reimbursement for both standard and complex endovascular repair, and the concentrated presence of leading device manufacturers including Medtronic, Cook Medical, W. L. Gore & Associates, and Endologix. North America hosts extensive hybrid operating room infrastructure and a deep base of vascular surgeons trained in EVAR, TEVAR, FEVAR, and BEVAR, supporting high procedure volumes across both elective and emergent settings. Continued regulatory approvals, including Medtronic's 2025 Endurant rAAA labeling update and Gore's Thoracoabdominal Branch Endoprosthesis approval, reinforce physician confidence and expand indicated use. Strong reimbursement, mature screening infrastructure, and proximity to leading manufacturers anchor the region's continued leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Aortic Aneurysm Stent Grafts market. The region's elevated CAGR is driven by rising cardiovascular disease burden, rapid expansion of hospital and vascular surgery infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's Volume-Based Procurement program is broadening access to domestically produced endografts from manufacturers such as Shanghai MicroPort Endovascular MedTech, India is scaling national aneurysm screening and awareness initiatives, and Japan continues to expand adoption of advanced TEVAR and fenestrated technology. Regional device makers, including MicroPort Endovastec and LifeTech Scientific, are broadening their product portfolios and securing regulatory approvals across Latin America and Southeast Asia in addition to their home markets. The combination of rising disease prevalence, expanding hospital capacity, and growing domestic manufacturing capability positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 44% of the global aortic aneurysm stent grafts market revenue in 2025. The United States dominates on the strength of its vascular surgery infrastructure, established screening pathway, favorable reimbursement, and the concentrated presence of leading device manufacturers, while continued regulatory approvals and label expansions reinforce its leadership.
Europe
Europe is a large and advanced regional market, supported by strong national health systems, established CE-marking pathways, and growing adoption of complex FEVAR and BEVAR procedures. Screening initiatives such as Czechia's 2025 national AAA pilot, alongside device innovation from JOTEC GmbH and other regional manufacturers, reinforce the region's role in advanced aortic repair across Germany, France, the United Kingdom, Italy, and Spain.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease prevalence, expanding hospital infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's Volume-Based Procurement program, India's expanding screening and treatment access, and the growth of regional manufacturers such as MicroPort Endovastec and LifeTech Scientific are accelerating adoption across the region.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding hospital and vascular surgery infrastructure, rising diagnosis of aortic aneurysms, and regulatory approvals extending device availability into markets such as Brazil and Argentina are gradually broadening access, while international partnerships support continued build-out of regional treatment capacity.
Aortic Aneurysm Stent Grafts Market Competitive Landscape
The Aortic Aneurysm Stent Grafts market is classified as Moderately Concentrated. A group of established multinational players with broad AAA and TAA portfolios and long-term clinical data, including Medtronic, W. L. Gore & Associates, Cook, and Terumo, anchors the top tier, while specialized and fast-scaling providers such as Shanghai MicroPort Endovascular MedTech, LifeTech Scientific, Cordis, JOTEC GmbH, Endologix LLC, and Lombard Medical compete through targeted anatomical indications, regional manufacturing, and complex-anatomy device innovation, increasing competition in the fastest-growing FEVAR and BEVAR segments.
The competitive landscape can be evaluated across the following dimensions:
Aortic Aneurysm Stent Grafts Market Recent Developmental Activities
In October 2025, Medtronic received FDA labeling approval for its Endurant stent graft system, adding ruptured abdominal aortic aneurysm (rAAA) clinical evidence and removing the rAAA treatment warning, becoming the first company to achieve this labeling update.
In April 2025, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. obtained regulatory approvals for its Talos Thoracic Stent Graft System in Brazil and Argentina, expanding availability of its advanced thoracic aortic repair technology.
Aortic Aneurysm Stent Grafts Market Segmentation
Aortic Aneurysm Stent Grafts Market by Product Type
Aortic Aneurysm Stent Grafts Market by Procedure Type
Aortic Aneurysm Stent Grafts Market by Graft Design
Aortic Aneurysm Stent Grafts Market by Material
Aortic Aneurysm Stent Grafts Market by Fixation Type
Aortic Aneurysm Stent Grafts Market by End User
Aortic Aneurysm Stent Grafts Market by Geography
Key Takeaways from the Aortic Aneurysm Stent Grafts Market Report Study
Target audience who can benefit from this Aortic Aneurysm Stent Grafts market report study
Q1. What is the growth rate of the aortic aneurysm stent grafts market?
The aortic aneurysm stent grafts market is projected to expand at a CAGR of 8.3% during the forecast period from 2026-2034.
Q2. What is the market size of the aortic aneurysm stent grafts market?
The aortic aneurysm stent grafts market is estimated at USD 3.85 billion in 2025 and is projected to reach USD 7.70 billion by 2034.
Q3. Which region dominates the aortic aneurysm stent grafts market?
North America dominated the aortic aneurysm stent grafts market with a 44% share of global revenue in 2025, supported by a high prevalence of aortic aneurysms, an established national screening pathway, broad reimbursement for endovascular repair, and the concentrated presence of leading device manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the aortic aneurysm stent grafts market?
The principal drivers are the rising global prevalence of aortic aneurysms among an aging population; the accelerating clinical shift from open surgical repair to minimally invasive EVAR and TEVAR; expanding aneurysm-screening programs, including Czechia's February 2025 national pilot; continuous technological advancement in low-profile and polymer-sealing graft design; and regulatory approvals and label expansions broadening indicated use.
Q5. Who are the major players in the aortic aneurysm stent grafts market?
The major players include Medtronic, Terumo, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (MicroPort Scientific Corporation), Cook, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Endologix LLC, Lombard Medical, and LifeTech Scientific, among others.
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.